Sanofi S.A. said on Friday its IFRS net sales in the third quarter of fiscal 2022 stood at €12.48 billion, rising 19.7% compared to the corresponding timeframe a year ago.
Net income was down 10.1% to €2.08 billion and earnings per share came in at €1.66, decreasing 9.8% from the third trimester in 2021.
CEO Paul Hudson praised "remarkable performance of 20% growth in both Specialty Care and Vaccines," which resulted in the company raising its business earnings per share guidance for the full year.